Advanced Parkinson's disease
Advanced Parkinson's disease
PD is an incurable neurological disorder of largely unknown aetiology that occurs due to the degeneration of dopaminergic neurons and the subsequent loss of dopamine throughout the brain. The advanced stages of PD are not well defined. Patients may exhibit problems with motor function such as tremor, rigidity and bradykinesia, as well as non-motor symptoms such as cognitive decline, pain, sleep disturbances, and autonomic dysfunction. Neuropsychiatric symptoms such as depression, anxiety, mood changes and apathy are also common. In essence, advanced PD is associated with a worsening of symptoms and a marked deterioration in the patient’s condition.
The medical management of advanced PD is complex. Disease modifying drugs such as levodopa, which work in early stages of PD, may become ineffectual or a source of severe side effects, requiring a change in medication schedule, the addition of other drugs, or surgical intervention. As such it becomes ever more challenging to achieve a treatment regimen that successfully counteracts the symptoms of advanced PD while at the same time minimising side effects. As life expectancy increases the number of patients reaching an advanced age and more advanced stages of the disease will also increase.
This website aims to serve as a valuable resource for physicians treating patients with advanced PD, providing information, highlighting advances in the latest research, collating the views of key opinion leaders, and listing forthcoming congresses in the field. This site serves to augment knowledge in the medical community of this complex and debilitating stage of PD, and thereby help inform and guide clinical decision making.
As an information resource for the scientific community, we are always looking for ways to improve our site. If you have any suggestions for additional content, please contact email@example.com. We welcome your input.
Idiopathic Parkinsons disease is commonly regarded as a prototypic movement disorder, neuropsychiatric features are prominent and affect the majority of patients. They include disorders of affect and...
- Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson's disease in Sweden
Although levodopa is the cornerstone treatment for PD, its short half-life limits the usefulness of the drug in later stages of the disease. Duodenal levodopa infusion (DLI) allows more stable plasma...
The American Society for Experimental NeuroTherapeutics (ASENT)’s goal is to encourage and advance the development of improved therapies for diseases and disorders of the nervous system.American Society for Experimental NeuroTherapeutics (ASENT): www.asent.org
The Congress of Neurological Surgeons (CNS) is a leader in education and innovation, providing its members with unparalleled educational opportunities. From the CNS Annual Meeting, presenting the highest-impact original science, to specialized education courses, the CNS offers the most advanced and...
Set to be the first annual meeting that is entirely electronic and paperless, the Paperless iPod touch® 2010 Philadelphia Annual Meeting is to be the most technologically advanced and innovative Annual Scientific Meeting in AANS’ history.Medical registrants of the 2010 AANS Paperless Annual...
Abstract deadline: 13 January 2011 Registration: €290 until 24th March, €365 until 14th April, €400 thereafter (member rates).The ENS meeting is also an international stage where those devoted to clinical or translational research in neurology can present and discuss the results of their work...